Search Medical Condition
Please enter condition
Please choose location from dropdown

Torquay, United Kingdom Clinical Trials

A listing of Torquay, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (23) clinical trials

Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)

Monoclonal gammopathy of unknown significance (MGUS) is a common haematological condition. It is characterised by proliferation of a B lymphocyte clone and it's associated antibody (paraprotein). In most cases there are no clinical symptoms, however, in a small number of individuals there may be an interaction of the paraprotein with ...

Phase N/A

0.0 miles

Learn More »

A Study for Older Adults With Acute Lymphoblastic Leukaemia

The study will establish baseline expectations for Event Free Survival (EFS), Overall Survival (OS), MRD responses and quality of life measures for older patients of all ages and pre-morbid states; disclose how best to use knowledge of pre-morbid characteristics to apply the appropriate intensity of therapy in order to balance ...

Phase

0.0 miles

Learn More »

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Chlorambucil (Chl) has been the mainstay of CLL treatment for half a century. However, frontline treatment has improved considerably over the last decade, first by the advent of fludarabine plus cyclophosphamide (FC), and more recently by the addition of the anti-CD20 antibody, rituximab, to FC. Although FC-based regimens are considerably ...

Phase

0.0 miles

Learn More »

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

The incidence of DLBCL is increasing and with an expanding elderly population, the incidence will continue to rise. Given that about 40% of cases of DLBCL occur in patients aged over 70 and the number of co-mobilities increases with age, research to investigate the optimal treatment of DLBCL in this ...

Phase

0.0 miles

Learn More »

Rapid Assessment of Potential Ischaemic Heart Disease With CTCA

DESIGN: Open parallel group randomised controlled trial of early computed tomography coronary angiography (CTCA) in patients presenting with suspected/confirmed acute coronary syndrome (ACS) to Emergency Departments (ED) and Medical Assessment Units. SETTING: 30 EDs, radiology, cardiology and acute medical services in tertiary/district general National Health Service (NHS) hospitals. TARGET POPULATION ...

Phase N/A

0.0 miles

Learn More »

The British Heart Foundation SENIOR-RITA Trial

The population is getting older and heart artery disease is the biggest killer in the UK. Over recent years, there have been improvements in medications and technologies to treat it, but these have been primarily tested in younger patients. Previous research studies suggest that older patients (75 years and over) ...

Phase N/A

0.0 miles

Learn More »

Study of Tumour Focused Radiotherapy for Bladder Cancer

RAIDER has a two stage design. Stage 1 will establish the feasibility of delivering DART in a multi-centre setting, and stage 2 will establish the toxicity of DART. 72 patients will be recruited in stage 1, with an additional 168 patients in stage 2. Both fractionation regimens in standard use ...

Phase

1.65 miles

Learn More »

UK Infinity Post-Market Clinical Follow-up Study

Study Title UK Post-Market Clinical Follow-Up Of The INFINITY Total Ankle System Study Design Prospective, multi-site, multi-year post-market clinical follow-up study Study Group Primary/Unilateral and/or bilateral Total Ankle Arthroplasty subjects implanted with INFINITY Total Ankle System N Subjects 500 with 10 sites Follow-Up Schedule Subject enrollment will consist of a ...

Phase N/A

1.89 miles

Learn More »

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Phase

1.89 miles

Learn More »

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Phase

1.89 miles

Learn More »